Inclusion Criteria : 
  -  Treatment - na√Øve or - pegIFN ( or IFN )  , and / or Ribavirin ( RBV ) and / or sofosbuvir ( PRS ) experienced with confirmed CHC , genotypes 1 , 2 , 3 , 4 , 5 , or 6 , with or without compensated cirrhosis , receiving combination therapy with the all oral GLE / PIB regimen according to standard of care , international guidelines and in line with the current local label . 
  -  May be enrolled up to 4 weeks after treatment initiation . 
  -  Patients must voluntarily sign and date Informed Consent Form prior to inclusion into the study . 
  -  Patient must not be participating or intending to participate in a concurrent interventional therapeutic trial . 
Exclusion Criteria : 
  -  None.